Market Cap : 927.86 M | Enterprise Value : 759.64 M | PE Ratio : At Loss | PB Ratio : 1.50 |
---|
NAS:SLGC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:SLGC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. SomaLogic's annualized Net Income for the quarter that ended in Mar. 2022 was $-15.92 Mil. SomaLogic's average Total Assets over the quarter that ended in Mar. 2022 was $709.64 Mil. Therefore, SomaLogic's annualized ROA % for the quarter that ended in Mar. 2022 was -2.24%.
The historical rank and industry rank for SomaLogic's ROA % or its related term are showing as below:
During the past 2 years, SomaLogic's highest ROA % was -18.46%. The lowest was -21.88%. And the median was -20.17%.
The historical data trend for SomaLogic's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, SomaLogic's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, SomaLogic's ROA % distribution charts can be found below:
* The bar in red indicates where SomaLogic's ROA % falls into.
SomaLogic's annualized ROA % for the fiscal year that ended in Dec. 2021 is calculated as:
ROA % | = | Net Income (A: Dec. 2021 ) | / | ( (Total Assets (A: Dec. 2020 ) | + | Total Assets (A: Dec. 2021 )) | / count ) |
= | -87.547 | / | ( (242.29 | + | 706.102) | / 2 ) | |
= | -87.547 | / | 474.196 | ||||
= | -18.46 % |
SomaLogic's annualized ROA % for the quarter that ended in Mar. 2022 is calculated as:
ROA % | = | Net Income (Q: Mar. 2022 ) | / | ( (Total Assets (Q: Dec. 2021 ) | + | Total Assets (Q: Mar. 2022 )) | / count ) |
= | -15.916 | / | ( (706.102 | + | 713.175) | / 2 ) | |
= | -15.916 | / | 709.6385 | ||||
= | -2.24 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2022) net income data. ROA % is displayed in the 30-year financial page.
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bankÂ’s ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
ROA % | (Q: Mar. 2022 ) | ||
= | Net Income | / | Total Assets |
= | -15.916 | / | 709.6385 |
= | (Net Income / Revenue) | * | (Revenue / Total Assets) |
= | (-15.916 / 91.92) | * | (91.92 / 709.6385) |
= | Net Margin % | * | Asset Turnover |
= | -17.32 % | * | 0.1295 |
= | -2.24 % |
Note: The Net Income data used here is four times the quarterly (Mar. 2022) net income data. The Revenue data used here is four times the quarterly (Mar. 2022) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Thank you for viewing the detailed overview of SomaLogic's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.
Blakeman Shaun M. | officer: Chief Financial Officer | C/O CANTEL MEDICAL CORP. 150 CLOVE ROAD LITTLE FALLS NJ 07424 |
Margulies Anne H. | director | C/O HENRY SCHEIN, INC. 135 DURYEA ROAD MELVILLE NY 11747 |
Post Richard A | director | 998 LACOSTA LANE LANE TREE CO 80124 |
Casdin Eli | director | 1350 AVENUE OF THE AMERICAS SUITE 1140 NEW YORK NY 10019 |
Cox Troy | director | C/O FOUNDATION MEDICINE, INC. C/O FOUNDATION MEDICINE, INC., 150 SECON CAMBRIDGE MA 02141 |
Meisel Ted D | director | |
Barchi Robert | director | |
Quake Stephen | director | C/O FLUIDIGM CORPORATION 7000 SHORELINE COURT, SUITE 100 SOUTH SAN FRANCISCO CA 94080 |
Lillis Charles M. | director | 13 CASTLE PINES DRIVE N CASTLE ROCK CO 80108 |
Harris Melody | officer: President and COO | 4801 WEST BYRON PLACE DENVER CO 80211 |
Gutierrez Ruben | officer: General Counsel | 6435 AVENIDA WILFREDO LA JOLLA CA 92037 |
Graves Amy | officer: Chief Accounting Officer | 926 PENDLETON AVENUE LONGMONT CO 80504 |
Smythe Roy | director, officer: Chief Executive Officer | 935 10TH STREET BOULDER CO 80302 |
M-lsh Ii Llc | 10 percent owner | 667 MADISON AVENUE C/O CORVEX MANAGEMENT LP NEW YORK NY 10065 |
C-lsh Ii Llc | 10 percent owner | 1350 6TH AVENUE SUITE 2600 NEW YORK NY 10019 |
From GuruFocus
Other Sources
By Zacks 2022-02-17
By Seekingalpha 2021-10-14
By Seekingalpha 2021-11-15
By Seekingalpha 2022-01-11